AEON Biopharma secures $15 million in private placement

  • Investing.com
  • Stock Market News
AEON Biopharma secures $15 million in private placement
Credit: © Reuters.

IRVINE, Calif. - AEON Biopharma, Inc. (NYSE AMEX: AEON, AEON WS), a clinical-stage biopharmaceutical company, has announced a $15 million private placement of senior secured convertible notes with Daewoong Pharmaceutical Co., LTD. The investment is set to support the late-stage clinical development of ABP-450, AEON's proprietary botulinum toxin complex, and general working capital needs.

The funding arrangement includes a two-part payment, with the first $5 million expected to close before the end of March 2024, and the remaining $10 million in April 2024. Following the completion of the second installment, AEON will expand its Board of Directors to include a designee from Daewoong's senior management team.

In a strategic move, AEON also terminated its forward purchase agreements (FPAs), allowing the FPA providers to retain 6,275,000 shares of common stock without further financial obligations. This decision aims to streamline AEON's capitalization structure.

AEON's focus on ABP-450 for debilitating medical conditions has shown promise with a successful end-of-Phase 2 meeting with the FDA, based on Phase 2 data for episodic migraine released in October 2023. The company is also planning an interim analysis of its ongoing Phase 2 program for chronic migraine in the second quarter.

ABP-450, manufactured by Daewoong under good manufacturing practice, is already approved for cosmetic use as Jeuveau. AEON holds exclusive development and distribution rights for therapeutic indications of ABP-450 in various territories, including the United States and the European Union.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Add Chart to Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100
Please try another search

Related Articles